Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

BioPharma innovation is rolling forward now – mega investments on the rise and advanced therapies are coming.

Contralant, March 20, 2023 The new frontiers of pharmaceutical innovation – according to investors ​ https://www.pharmaceutical-technology.com/sponsored/the-new-frontiers-of-pharmaceutical-innovation-according-to-investors/

But there are some positive signs. The Covid-19 pandemic created a new appetite for pharmaceutical innovation – dulled by recent economic troubles, but ravenous compared to pre-2020 averages. The mRNA technology that enabled the largest and fastest vaccine rollout in history is the tip of the innovation iceberg. Research – and money – going into even more advanced gene therapies is ramping up. In addition, mega deals – investments worth $100m or more – are on the rise. Contrast 2022 with 2019. In addition to a higher overall volume of investment, mega-investors are staking greater claims in pharmaceutical innovation. On average, mega-deals made up 45% of investments in 2022, contrasting with just 29% of investments in 2019. The venture capital world has settled around a new equilibrium where investors are willing to spend more money more often on the innovations of the future. Some regions and therapies have become particularly fertile growth areas; entrepreneurs who are in the know stand to benefit enormously.

Sign in to recut, update, or save this card.